Under the terms of the deal, HDB will have access to Luxcel's assays and technologies for mitochondrial function, metabolism, and toxicity.
LifeCodexx's PrenaTest will be available to women in Malaysia, Singapore, Thailand, Brunei, Vietnam, the United Arab Emirates, and elsewhere in the Middle East.
BKare will provide marketing and certain other services to Vantari, which offers genetic testing, as well as molecular laboratory and toxicology services.
Agilent and CRO PureHoney will develop new applications for the RapidFire 365 system, including workflows for pharmaceutical research, forensics, and metabolomics.
Teneovita will distribute Biocept's test services to hospitals, oncology centers, and individual medical practices throughout the country.
CombiMatrix said the move will increase access to the test in the state for women experiencing recurrent pregnancy loss.
Under the terms of the agreement, M3 and G-TAC will promote 14 Pathway tests through G-TAC's personalized medicine platform connected to M3's physician network.
Under the agreement, Genomic Health will make an undisclosed equity investment in Epic Sciences, and will have exclusive rights to market its test in the US.
The agreement covers GynTect, which uses epigenetic biomarkers and methylation-specific PCR to determine if an HPV-positive patient is at risk for developing cervical cancer.
The deal gives SouthGenetics marketing rights for MDxHealth's ConfirmMDx test for prostate cancer in 12 countries, including Mexico, Argentina, and Colombia.
Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.
An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.
At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.
In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.